Overview

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation

Status:
Not yet recruiting

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

The primary endpoint of this study is to assess the effects of a single IV dose of mavrilimumab on the acute inflammatory response in patients with severe COVID-19 pneumonia

Phase:

Phase 2

Details

Lead Sponsor:

Virginia Commonwealth University

Treatments:

Antibodies, Monoclonal
Mavrilimumab